Viking Therapeutics (VKTX) Stock: Financial Performance Highlights 22% Revenue Growth and 44% Profit Increase in 2025

Key Highlights

• 2025 revenue increases 21.9% with substantial profit growth
• Adjusted EBITDA expands 38.8% with improved margins
• Fourth quarter revenue climbs 27.8% driven by fleet expansion
• 2026 advance reservations grow 13% to $5.96B
• VKTX shares decline 1.48% despite robust earnings

Shares of Viking Therapeutics, Inc. (VKTX) ended trading at $33.34, reflecting a 1.48% decline for the session. During this time, Viking Holdings Ltd announced impressive fourth-quarter and complete fiscal year 2025 financial outcomes. The organization demonstrated substantial revenue advancement and considerable profit growth while maintaining strong advance reservations heading into 2026.

Viking Therapeutics, Inc., VKTX

Full Year 2025 Financial Results and VKTX Performance

Viking Holdings achieved total revenue of $6.5 billion throughout fiscal year 2025, representing a 21.9% increase versus the previous year. The organization also expanded adjusted gross margin by 22.6% to reach $4.29 billion.

Full-year net income totaled $1.15 billion. Adjusted net income attributable to Viking Holdings jumped 43.9% to $1.17 billion. Diluted earnings per share came in at $2.57, with adjusted EPS posting $2.61.

The company’s adjusted EBITDA surged 38.8% to $1.87 billion. Net yield demonstrated a 7.4% year-over-year improvement to $583. Net leverage showed meaningful strengthening, declining from 2.4x to 1.1x by the conclusion of 2025.

Q4 Performance Demonstrates Enhanced Capacity and Margin Strength

Throughout the fourth quarter, Viking expanded capacity passenger cruise days by 14.7% versus the prior-year period. This growth stemmed from launching six additional river vessels alongside two new ocean ships. Occupancy levels reached 95%, contributing to enhanced revenue generation.

Fourth quarter total revenue advanced 27.8% to $1.72 billion. Gross margin expanded 38.2% to $652.1 million. Adjusted gross margin increased 27.3% to $1.11 billion, with net yield improving 7.7% to $546.

Additionally, adjusted EBITDA jumped 51.3% to $462.8 million. Net income totaled $300.3 million, representing significant growth from $104.2 million in the comparable quarter. Adjusted net income rose 49.1% to $297.7 million, with diluted EPS climbing to $0.67.

Strong 2026 Reservations and Fleet Growth Drive Future Prospects

Viking commenced 2026 with expanded operational capacity alongside robust reservation trends. Core product capacity exceeds the 2025 season by 7%. By mid-February 2026, the organization had secured sales for 86% of capacity passenger cruise days.

Advance reservations for the 2026 season reached $5.96 billion. This represented a 13% enhancement compared to the equivalent timeframe in the previous year. Advance reservations per passenger cruise day increased 6% to $859.

The financial position reflected strong liquidity alongside prudent capital allocation. The company concluded 2025 holding $3.8 billion in cash plus a $1.0 billion unused revolving credit facility. Scheduled principal obligations for 2026 amount to $396.8 million, with deferred revenue standing at $4.6 billion.

Viking maintained fleet development through additional shipbuilding agreements. The organization anticipates receiving two ocean vessels and ten river vessels during 2026. Management also obtained options for supplementary ocean ships and committed to two expedition vessels scheduled for 2030 and 2031 arrivals.

Viking manages over 100 vessels throughout river and ocean destinations globally. The organization focuses on travelers prioritizing destination-focused and culturally immersive experiences. Robust 2025 results combined with elevated 2026 reservations establish a foundation for sustained earnings growth.

The post Viking Therapeutics (VKTX) Stock: Financial Performance Highlights 22% Revenue Growth and 44% Profit Increase in 2025 appeared first on Blockonomi.